Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines

Journal of Travel Medicine

Volumn 6, Issue 4, 1999, Pages 228-233

  Bovier, Patrick A ^a   Althaus, Beat ^c   Glueck, Reinhard ^c   Chippaux, André ^b   Loutan, Louis ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b INSTITUT PASTEUR   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; STAMARIL; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; HEADACHE; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IMMUNOGENICITY; INJECTION SITE; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYALGIA; PAIN; SEROCONVERSION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; TROPICAL DISEASE; VACCINATION; VIRUS INFECTION; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

EID: 0032735197     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1708-8305.1999.tb00523.x     Document Type: Article

References (25)

1. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271:1328-1334.
2. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327:453-457.
3. Gutersohn T, Steffen R, Van Damme P, et al. Hepatitis A infection in aircrews: risk of infection and cost-benefit analysis of hepatitis A vaccination. Aviat Space Environ Med 1996; 67:153-156.
4. Ambrosch F, Wiedermann G, Jonas S, et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15:1209-1213.
5. Just M, Berger R, Dreschsler H, et al. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks. Vaccine 1992; 10:737-739.
6. Loutan L, Bovier P, Althaus B, et al. Inactivated virosome hepatitis A vaccine. Lancet 1994; 343:322-324.
7. Robertson S, Hull B, Tomori O, et al. Yellow fever. A decade of reemergence. JAMA 1996; 276:1157-1162.
8. Yvonnet B, Coursaget P, Deubel V, et al. Simultaneous administration of hepatitis B and yellow fever vaccine. J Med Virol 1986; 19:307-311.
9. Mouchon D, Pignon D, Vicens R, et al. Étude de la vaccination combinée rougeole-fièvre jaune chez l'enfant africain âgé de 6 à 10 mois. Bull Soc Path Exot 1990; 83:537-551.
10. Ambrosch F, Fritzell B, Gregor J, et al. Combined vaccination against yellow fever and typhoid fever: a comparative trial. Vaccine 1994; 12:625-628.
11. Bovier P, Loutan L. Vaccin inactive a virosome contre l'hepatite A: variation de la reponse immunitaire on cas d'administration simultanee d'autres vaccins, Abstract no P213. Schweiz Med Wschr 1993; 123:10.
12. WHO. Prevention and control of yellow fever in Africa. The World Health Organization, Geneva, 1986.
13. Felsenfeld O, Wolf RH, Gyr K, et al. Simultaneous vaccinations against cholera and yellow fever. Lancet 1973; 1:457-458.
14. Kallinowski B, Bock HL, Clemens R, et al. Immunogenicity and reactogenicity of a combined hepatitis A/B candidate vaccine: first results. Liver 1996; 16:271-273
15. Ambrosch F, Andre FE, Delem A, et al. Simultaneous vaccination against hepatitis A and B: results of a controlled study. Vaccine 1992; 10:142-145.
16. Van Hoecke C, Lebacq E, Beran J, et al. Cor comittant vaccination against hepatitis A and typhoid fever. J Travel Med 1998; 5:116-120.
17. Vodopija I, Clemens R, Baklaic Z, et al. Feasibility of combined administration of hepatitis A and typhoid fever vaccines for vaccination of travelers. J Travel Med 1995; 2:120.
18. Mengiardi B, Berger R, Just M, et al. Virosomes as carriers for combined vaccines. Vaccine 1995; 13:1306-1315.
19. Schutze M, Deriaud E, Przewlocki G, et al. Carrier-induced epitopic suppression is initiated through clonal dominance. J Immunol 1989; 142:2635-2640.
20. Holzer BR, Hatz C, Schmidt-Sissolak D, et al. Immunogenicity and adverse effects of inactivated virosome versus alumadsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 1996; 14:982-986.
21. Maiwald H, Jilg W, Bock H, et al. Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine. Vaccine 1997; 15:346-348.
22. Goudeau A, Denis F, Mounier M, et al. Comparative multicentre study of the immunogenicity of different hepatitis B vaccines in healthy volunteers. Postgrad Med J 1987; 63: 125-128.
23. Wood RC, MacDonald KL, White KE, et al. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993; 270: 2935-2939.
24. Roome AJ, Walsh SJ, Cartter ML, et al. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993; 270:2931-2934.
25. Margolis HS, Presson AC. Host factors related to poor immunogenicity of hepatitis B vaccine in adults: another reason to immunize early. JAMA 1993; 270:2971-2972.